Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer

Combining an immune checkpoint inhibitor with batiraxcept (AVB-S6-500), an AXL inhibitor that acts via selective binding to growth arrest-specific protein 6 (GAS6), may improve anti-tumor immunity in platinum-resistant ovarian cancer (PROC). This phase 1b trial of durvalumab in combination with esca...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	iScience 2024-05, Vol.27 (5), p.109801-109801, Article 109801
Hauptverfasser:	Knisely, Anne, Hinchcliff, Emily M., Gardiner, Elisabeth, Rangwala, Reshma, Lito, Kathryn, Fellman, Bryan, Yuan, Ying, Sood, Anil K., Westin, Shannon N., Lu, Karen H., Jazaeri, Amir A.
Format:	Artikel
Sprache:	eng
Schlagworte:	CFTR CRISPR Cystic fibrosis Gene editing Gene therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!